Insider buying last 90 days
No open-market insider purchases were filed for DOCS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every DOCS insider filing, plotted on the chart in Gekko.Open DOCS in Gekko
NYSE: DOCS
Doximity (DOCS) Stock Analysis & Forecast
Sep 28 close
$26.20−0.15 (−0.6%)
Gekko Brief
AI summaryThis week's news centers on a cluster of securities class action announcements from multiple law firms, including Robbins Geller Rudman & Dowd, Rosen Law Firm, Robbins LLP, Bronstein Gewirtz & Grossman, Levi & Korsinsky, and Kaplan Fox, all pointing investors toward a November 16, 2026 lead plaintiff deadline. The underlying allegations concern claims that Doximity overstated the revenue impact of its "Newsfeed" product while losing market share to competitors offering more favorable pricing and engagement models, with the relevant purchase period spanning August 8, 2024, to May 13, 2026.
DOCS closes at $26.20, down 0.6%, sitting between its 50-day average of $24.53 and 200-day average of $27.12. The GekkoIndex reads 55, placing the stock in the Neutral zone. Price sits 3.2% below Gekko Fair Value of $27.07. Over the past year the stock is down 64.8%, though the three-month return stands at 27.2% and the one-month return at 2.4%.
The next earnings report is scheduled for 5 November 2026 after close, 37 days out and beyond a typical 20-trading-day holding window. The prior quarter showed revenue of $157 million, up 7% year-over-year, with adjusted EBITDA of $75 million, though EPS of $0.14 missed the $0.16 estimate, triggering a 26.6% reaction. No insider, Congress, or unusual options activity appears in the recent windows. Seasonality over the next 20 trading days has averaged -10.5% across 5 years, with 0 of those years positive. Analyst consensus stands at 7 buy, 7 hold, and 2 sell ratings among 16 firms, with a consensus target of $29.94.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Doximity price vs fair value
Close $26.20200-day averageGekko Fair Value $27.07
Doximity quick facts
- Market cap
- $4.90B
- P/E ratio
- 32.1
- Forward P/E
- 19.8
- EPS, TTM
- $0.82
- Revenue, TTM
- $655.6M
- Profit margin
- 25.5%
- Dividend yield
- —
- Beta
- 1.25
- Volume
- 2.93M avg 2.65M
- 1-year return
- −64.8%
- Typical daily move
- ±3.7%
- Typical 20-day move
- ±10.6%
- 50-day average
- $24.53
- 200-day average
- $27.12
- Next earnings
- Nov 5 after close
- Shares outstanding
- 127.3M
Doximity swing-trade checklist
Doximity scores 1 supportive, 3 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive3 mixed1 headwind
- Trendmixed
Averages disagree
Close $26.20 sits between the 50-day ($24.53) and 200-day ($27.12) averages, or the averages disagree.
See the chart - GekkoIndexmixed
55, Neutral
Reading 55 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
3.2% below
Price is within 5% of Gekko Fair Value (3.2% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−10.5% on average
From this point in the calendar, the next 20 trading days averaged −10.5% over 5 years, rising in 0 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Doximity stock chart and price history
Doximity closed at $26.20 on Sep 28, 2026, −64.8% over the past year, inside a 52-week range of $17.15 to $76.51.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +2.4%
- 3 months
- +27.2%
- 6 months
- +10.6%
- 1 year
- −64.8%
The full DOCS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DOCS in Gekko
Follow Doximity through every session
Put DOCS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track DOCS in GekkoFree for 7 days. No credit card required.
About Doximity
Doximity runs a cloud-based digital platform built for healthcare practitioners across the United States. Members use it to connect with fellow professionals, coordinate patient care, hold remote consultations, keep up with medical news and research, and support their career development. The platform is best known as a networking and productivity hub for doctors and other clinicians.
The company draws its business primarily from pharmaceutical companies and healthcare organizations, which make up its main customer base. This positions Doximity as a service provider to institutions within medicine rather than a direct-to-consumer product, with its tools built around the daily needs of practicing clinicians.
Doximity was founded in 2010, originally under the name 3MD Communications, Inc., before adopting its current name later that same year. The company is headquartered in San Francisco, California. Its shares are listed on the NYSE under the ticker DOCS.
- Listed
- NYSE
- Sector
- Technology services
- Industry
- Packaged software
- Website
- doximity.com
Doximity GekkoIndex: the smart money zone
Doximity’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55, in the Neutral zone, up 3.7 points over five sessions.
55Neutral
Up 3.7 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 70 | −1.5% | −0.7% |
| Accumulation | 202 | +1.0% | −2.0% |
| Neutral (current zone) | 350 | +0.4% | +3.8% |
| Distribution | 39 | +0.2% | −2.4% |
| Selling | 11 | −6.2% | −8.7% |
Average DOCS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the DOCS price, zone by zone.Track DOCS in Gekko
Is Doximity stock overvalued? Gekko Fair Value
Doximity trades 3.2% below Gekko Fair Value of $27.07, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Doximity shares are worth, recalculated every trading day.
$27.07
Gekko Fair Value, Sep 29, 2026
3.2% below fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open DOCS in Gekko
Doximity insider and Congress trading
No open-market insider purchases were filed for Doximity, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in DOCS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for DOCS, plotted on the chart in Gekko.Open DOCS in Gekko
Buybacks
Doximity has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $91.63M
- As a share of market cap
- 1.87%
- Trailing four quarters
- $400.9M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds DOCS.
0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Doximity earnings: next date and track record
Doximity reports on Nov 5, 2026, after the close (37 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 37 days away
- EPS estimate
- $0.34
- Revenue estimate
- $170.6M
6 of 8reports beat the EPS estimate
±24.4%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Doximity reported a strong Q1 FY2027: revenue of $157M, up 7% year-over-year, and adjusted EBITDA of $75M (48% margin), both beating the high end of guidance. Management emphasized that FY2027 is an "AI investment year," expanding AI spending while maintaining high software margins. The company highlighted independent validation (NOHARM study) showing Doximity Ask leading U.S. models on clinical accuracy and safety, attributing outperformance to a proprietary drug reference and 12,000 physician PeerCheck editors. AI product momentum (Ask, AI search, and Scribe) drove higher usage and engagement, accelerating prompts and onboarding of initial AI search customers (a couple dozen programs), with expectations that most contracted AI search revenue to date will be recognized in Q3. The sales mix remained concentrated: 127 pharma and hospital customers generate >$500k ARR (83% of revenue); top 20 NRR was 112% and overall NRR 107% (TTM). Management signaled confidence in the long-term TAM and unit economics of AI search (stated >10x revenue per search vs cost today) and described strong pipeline activity across pharma, hospitals, and SMBs, while acknowledging a still-tight but stabilizing buying environment.
- Guidance
- Q1 results beat guidance. Management indicated revenue guidance to grow around 5% for the rest of FY2027. They expect the majority of AI search revenue contracted to date to be recognized in Q3 of FY2027. Management also stated they will expand AI investment in FY2027 (an "AI investment year").
- Risks flagged
- Legal and regulatory risk around clinical AI (lawsuits and AI steering committee concerns); tight macro/budget environment for buyers (though stabilizing); customer concentration risk (large customers account for a high share of revenue); execution risks related to product rollout, EHR integrations and monetization timing; potential reputational risk if AI outputs produce clinical errors.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $0.14 est $0.16 | $156.6M est $151.8M | +26.6% |
| May 13, 2026 | $0.26 est $0.28 | $145.4M est $144.0M | −31.9% |
| Feb 5, 2026 | $0.46 est $0.45 | $185.1M est $181.6M | −21.3% |
| Nov 6, 2025 | $0.45 est $0.38 | $168.5M est $157.9M | −15.2% |
| Aug 7, 2025 | $0.36 est $0.30 | $145.9M est $139.5M | +14.5% |
| May 15, 2025 | $0.38 est $0.27 | $138.3M est $133.7M | −11.7% |
| Feb 6, 2025 | $0.45 est $0.31 | $168.6M est $134.1M | +36.3% |
| Nov 7, 2024 | $0.30 est $0.25 | $136.8M est $127.1M | +37.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Doximity stock forecast and analyst price targets
Analysts’ average 12-month price target for Doximity is $29.94, +14.3% from the last close, from 16 firms rating the stock in the last 90 days.
$29.94consensus 12-month target, +14.3% from the last close
Now $26.20Avg $29.94
Low $18High $47
Each firm’s latest rating in the last 90 days: 16 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 23 | Bank of America Securities | $20 | −23.7% |
| Sep 18 | Morgan Stanley | $35 | +33.6% |
| Sep 14 | Morgan Stanley | $35 | +33.6% |
| Sep 8 | Freedom Capital Markets | $27 | +3.1% |
| Aug 20 | Barclays | $27 | +3.1% |
+3.8%average 20-day move after past Neutral readings
−10.5%average move over the next 20 trading days in the last 5 years
±3.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Doximity seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Doximity averaged −10.5% across the last 5 years, rising in 0 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.8% | 3 of 5 |
| Next 10 trading days | −6.4% | 2 of 5 |
| Next 15 trading days | −7.5% | 2 of 5 |
| Next 20 trading days | −10.5% | 0 of 5 |
| Next 30 trading days | −2.4% | 2 of 5 |
For scale, DOCS’s typical 20-trading-day move in either direction is about 10.6%.
Doximity market cap and key statistics
Doximity’s market cap is $4.90B, with a P/E ratio of 32.1 and revenue of $655.6M over the last twelve months.
Valuation
- Market cap
- $4.90B
- P/E ratio
- 32.1
- Forward P/E
- 19.8
- EPS, TTM
- $0.82
- Gekko Fair Value
- $27.07
Trading
- Volume
- 2.93M
- Avg volume, 20 days
- 2.65M
- 52-week high
- $76.51
- 52-week low
- $17.15
- Shares outstanding
- 127.3M
Financials
- Revenue, TTM
- $655.6M
- Profit margin
- 25.5%
- Return on equity
- 17.2%
- Quarterly earnings growth, YoY
- −51.9%
Risk and income
- Beta
- 1.25
- Typical daily move
- ±3.7%
- Typical 20-day move
- ±10.6%
Doximity stock news this week
Coverage of Doximity this week reads negative: 0 positive, 1 neutral and 12 negative headlines.
- INVESTOR DEADLINE: Doximity, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit before November 16, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces - DOCSBusiness Wire, Sep 28
- Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Doximity, Inc. (DOCS)GlobeNewsWire, Sep 28
- ROSEN, A LONGSTANDING LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCSTMX Newsfile, Sep 28
- Robbins LLP is Investigating Allegations that Doximity, Inc. Failed to Disclose to Investors it Was Losing Market Share to its Competitors With More Favorable Pricing and Engagement ModelsNewsfile Corp, Sep 28
- Bronstein, Gewirtz & Grossman LLC Urges Doximity, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire, Sep 28
- Deadline Approaching: Doximity, Inc. (DOCS) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. SmithGuruFocus, Sep 28
Doximity peers
Doximity’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| MSFTMicrosoft | Neutral | 17.3% above |
| PLTRPalantir Technologies | Neutral | 15.7% above |
| ORCLOracle | Accumulation | 25.9% below |
| PANWPalo Alto Networks | Neutral | 16.1% above |
| CRWDCrowdStrike | Neutral | 27.2% above |
| CRMSalesforce | Neutral | 5.9% below |
A peer links to its own page where one exists.
Doximity stock FAQ
What is Doximity’s market cap?
Doximity’s market cap is $4.90B at the Sep 28, 2026 close of $26.20, with 127.3M shares outstanding. The shares trade on a P/E ratio of 32.1.
What is the Doximity stock forecast?
The consensus analyst 12-month price target for Doximity is $29.94, +14.3% from the last close. Of the 16 firms that rated the stock in the last 90 days, 7 rate it a buy, 7 a hold and 2 a sell. Gekko doesn’t publish price predictions of its own.
Is Doximity stock overvalued or undervalued?
On Gekko’s estimate Doximity is about fair value: the Sep 28, 2026 close of $26.20 is 3.2% below Gekko Fair Value of $27.07. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Doximity report earnings next?
Doximity is expected to report on Nov 5, 2026, after the market closes (37 days away). Analysts expect earnings of $0.34 per share on revenue of $170.6M. Doximity beat the earnings estimate in 6 of its last 8 reports, moving 24.4% on average across the report.
What is Doximity’s 52-week high and low?
Doximity’s 52-week high is $76.51 and its 52-week low is $17.15; it closed at $26.20 on Sep 28, 2026, −64.8% over the past year. Over the last five years the shares peaked at $91.25 on Oct 7, 2021.
Is Doximity stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (earnings risk), 3 as mixed (trend, gekkoindex and fair value) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Doximity the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.